// App-Quantinova.ai

: What is the Incidence and Severity of Abnormal Uterine Bleeding Associated with Rivaroxaban in the Treatment of VTE and is there an Impact on Treatment Satisfaction? Early Results from the ‘Follow‐up in Rivaroxaban Patients in Setting of Thromboembolism’ (FIRST) Registry

Researchers

Presenter

  • V. Speed

Principal Investigators

  • V. Auyeung

  • J. Patel

  • B. Nemeth

  • L. Roberts

  • R. Patel

  • R. Arya

Medical Centers

  • Kings College London, London, United Kingdom

  • King's College London, Institute of Pharmaceutical Science, London, United Kingdom

  • Leiden University Medical Center, Department of Clinical Pharmacy and Toxicology, Leiden, Netherlands

Locations

  • United Kingdom

  • Netherlands

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

  • Blood/haematological Diseases

  • Cardiovascular (CVS)

Disease

  • Venous thrombosis

Biomarkers

  • N/A

Drug/Treatment

  • rivaroxaban

Outcome

  • N/A

Study Design

  • Multicenteric

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved